Filters

1956 - 2079532470 - 256916
Reset filters

Settings

Search Results

Now showing 1 - 10 of 69
  • No Thumbnail Available
    PublicationMetadata only
    Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients
    (2014-01-01) Sutima Luangdilok; Norasate Samarnthai; Krittiya Korphaisarn; Mahidol University
    in locally advanced breast cancer. Methods: Medical records of patients who had undergone neoadjuvant chemotherapy for breast cancer between January 2007 and September 2011 were retrospectively reviewed, and the pCR rates were calculated ac­cording to three...­adjuvant chemotherapy, 167 patients (93.3%) had locally ad­vanced breast cancer and 12 patients (6.7%) had early-stage breast cancer. The majority of patients (152 patients, 89.4%) re­ceived anthracycline-based neoadjuvant chemotherapy. The ob­jective clinical response
  • No Thumbnail Available
    PublicationMetadata only
    Hospice utilization and end-of-life care in metastatic breast cancer patients at a comprehensive cancer center
    (2015-01-01) Tracey L. O'Connor; Nuttapong Ngamphaiboon; Adrienne Groman; Debra L. Luczkiewicz; Sarah M. Kuszczak; Pei C. Grant; Christopher W. Kerr; Roswell Park Cancer Institute; Mahidol University; Center for Hospice and Palliative Care; Michael E. DeBakey VA Medical Center
    © 2015, Mary Ann Liebert, Inc. Background: Metastatic breast cancer patients have many options for therapy and may be at risk for late or absent hospice referrals, which make meaningful improvements in symptoms and quality of life difficult... to achieve.Objective: We aimed to examine hospice utilization, status of patients on admission, and quality of care of patients treated for metastatic breast cancer from 1999 to 2010 at a National Cancer Institute (NCI)-designated comprehensive cancer center
  • No Thumbnail Available
    PublicationMetadata only
    A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer
    (2013-02-01) Suthinee Ithimakin; Adune Ratanawichitrasin; Vutisiri Veerasarn; Charuwan Akewanlop; Nopadol Soparattanapaisarn; Supakorn Rojananin; Pornchai O-charoenrat; Poramaporn Prasarttong-osoth; Vichien Srimuninnimit; Mahidol University
    Objective: Although anthracycline-based regimen is standard neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC), there is some concern over its toxicities such as alopecia and cardiotoxicity. Gemcitabine is another active agent... in metastatic breast cancer after failure to anthracycline with less toxicity. The objective of the present study is to evaluate the efficacy and safety of the combination of gemcitabine and carboplatin as NAC in LABC. Material and Method: Patients
  • No Thumbnail Available
    ItemMetadata only
    Significance of Hypofractionated Radiotherapy in Postoperative Irradiation for Breast Cancer: An Asian Multi-institutional Prospective Study
    (2023-01-01) Okonogi N.; Kono S.; Karasawa K.; Banu P.A.; Xu X.; Erawati D.; Adylkhanov T.; Jang W.I.; E. Y.; Calaguas M.J.; Thephamongkhol K.; Dung T.A.; Ng W.N.P.; Kato S.; Mahidol University
    Aims: There is a need for the adequate distribution of healthcare resources in Southeast Asia. Many countries in the region have more patients with advanced breast cancer who are eligible for postmastectomy radiotherapy (PMRT). Therefore..., it is critical that hypofractionated PMRT is effective in most of these patients. This study investigated the significance of postoperative hypofractionated radiotherapy in patients with breast cancer, including advanced breast cancer, in these countries
  • No Thumbnail Available
    PublicationMetadata only
    Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A clinical trial
    (2018-07-01) Melanie Royce; Thomas Bachelot; Cristian Villanueva; Mustafa Özgüroglu; Sergio J. Azevedo; Felipe Melo Cruz; Marc Debled; Roberto Hegg; Tatsuya Toyama; Carla Falkson; Joon Jeong; Vichien Srimuninnimit; William J. Gradishar; Christina Arce; Antonia Ridolfi; Chinjune Lin; Fatima Cardoso; Champalimaud Foundation; Yonsei University Health System; University of New Mexico; Istanbul Üniversitesi; Centre Hospitalier Universitaire de Besancon; The University of Alabama at Birmingham; Le Centre Régional de Lutte Contre le Cancer Léon Bérard; Hospital de Clinicas de Porto Alegre; Novartis Pharma S.A.S.; Northwestern University Feinberg School of Medicine; Faculty of Medicine, Siriraj Hospital, Mahidol University; Universidade de Sao Paulo - USP; Institut Bergonie; Nagoya University; Novartis Pharmaceuticals Corporation; Instituto Brasileiro de Controle do Câncer
    © 2018 American Medical Association. IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. OBJECTIVE... To investigate the combination of everolimus plus endocrine therapy in first-line and second-line treatment settings for postmenopausal women with estrogen receptor-positive, human epidermal growth receptor 2-negative advanced breast cancer. DESIGN, SETTING
  • No Thumbnail Available
    PublicationMetadata only
    Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant paclitaxel with bevacizumab
    (2010-12-01) Valentina Lazzati; Justyna Zygoń; Visnu Lohsiriwat; Paolo Veronesi; Jean Yves Petit; Istituto Europeo di Oncologia; Mahidol University
  • No Thumbnail Available
    ItemMetadata only
    Post-biopsy to Surgery Interval Tends to Increase Axillary Nodal Metastasis, Especially in Early Breast Cancer Patients
    (2024-01-01) Prasitviset P.; Pisarnturakit P.; Ratanawichitrasin A.; Prasitviset P.; Mahidol University
    ) on the proportion of metastatic axillary lymph nodes (N-Staging), controlled by tumor size. Materials and Methods: A cross-sectional study of primary breast cancer patients treated between October 2021–December 2022 at the Division of Head Neck and Breast Surgery... was noted in patients with delayed surgery. No significant additional differences were found concerning breast cancer subtype, pathological grading, or lympho-vascular/perineural invasion. Conclusion: Increasing TTS was significantly associated with more
  • No Thumbnail Available
    ItemMetadata only
    Incidence and Prognostic Values in Human Epidermal Growth Factor Receptor 2-Low Expression Metastatic Breast Cancer in Southeast Asian Population: A 10-Year Retrospective Study
    (2024-09-01) Dajsakdipon T.; Pipatsakulroj W.; Dejthevaporn T.; Dajsakdipon T.; Mahidol University
    information regarding the epidemiology and clinical outcomes of metastatic HER2-low expression breast cancer in a Southeast Asian population is lacking. METHODS: This retrospective cohort study was performed to analyze data from patients with de novo advanced... patients, regardless of first-line chemotherapy or endocrine therapy. CONCLUSION: This study revealed the incidence and clinical outcomes of HER2-low expression in de novo advanced breast cancer, suggesting favorable outcomes, particularly in HR-positive
  • No Thumbnail Available
    ItemMetadata only
    Cancer stages and mortality risk of breast cancer between women with and without disabilities: A national population-based cohort study in Taiwan
    (2024-01-01) Inchai P.; Tsai W.C.; Chiu L.T.; Kung P.T.; Inchai P.; Mahidol University
    between women with and without disabilities regarding breast cancer stages and evaluated the probability of developing an advanced stage and the mortality risk of breast cancer. Methods: This study conducted a nationwide retrospective cohort study using... the National Health Insurance Research Database and other nationwide databases. Our participants were newly diagnosed breast cancer patients, including women with and without disabilities, between 2004 and 2010. We matched both of them with propensity score
  • No Thumbnail Available
    PublicationMetadata only
    Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
    (2013-01-01) Kathleen I. Pritchard; Howard A. Burris; Yoshinori Ito; Hope S. Rugo; Shaker Dakhil; Gabriel N. Hortobagyi; Mario Campone; Tibor Csöszi; José Baselga; Puttisak Puttawibul; Martine Piccart; Daniel Heng; Shinzaburo Noguchi; Vichien Srimuninnimit; Hugues Bourgeois; Antonio Gonzalez Martin; Karen Osborne; Ashok Panneerselvam; Tetiana Taran; Tarek Sahmoud; Michael Gnant; University of Toronto; Sarah Cannon Research Institute; Cancer Institute Hospital of Japan Foundation for Cancer Research; UCSF Helen Diller Family Comprehensive Cancer Center; Cancer Center of Kansas; University of Texas MD Anderson Cancer Center; Centre de Recherche en Cancérologie; Hetenyi Geza County Hospital; Memorial Sloan-Kettering Cancer Center; Prince of Songkla University; Institut Jules Bordet; University of Calgary; Osaka University; Mahidol University; Centre Jean Bernard; MD Anderson Cancer Center, Madrid; Novartis International AG; Novartis Pharmaceuticals Corporation; Medizinische Universitat Wien
    with HR+advanced breast cancer recurring/progressing after treatment with NSAIs. Safety and efficacy data in elderly patients are reported at 18-month median follow-up. Results Baseline disease characteristics and treatment histories among the elderly... deaths. Conclusion Adding EVE to EXE offers substantially improved PFS over EXE and was generally well tolerated in elderly patients with HR+advanced breast cancer. Careful monitoring and appropriate dose reductions or interruptions for AE management